A systematic modification of the caffeinyl core and substituents of the reference compound (E)-8-(3-chlorostyryl)caffeine led to the 9-deazaxanthine derivative (E)-6-(4-chlorostyryl)-1,3,5,-trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f) which acts as a dual antagonist of human A2a/MAO-B inhibitor (Ki(A2A) = 260 nM; IC50(MAO-B) = 200 nM; IC50(MAO-A) = 10 M) and dose dependently counteracts haloperidol-induced catalepsy in mice from 30 mg/kg by the oral route. The compound is the best balanced A2A antagonist /MAO-B inhibitor reported to date and it could be considered as a new lead in the field of anti-Parkinson’s agents. A number of analogs of 17f were synthesized and qualitative SARs are discussed. Two analogs of 17f, namely 18b and 19a, inhibit MAO-B with IC50 of 68 nM and 48 nM, respectively, being from five to seven folds more potent than the prototypical MAO-B inhibitor deprenyl (IC50 = 334 nM).
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors / Rivara, Silvia; Piersanti, G.; Bartoccini, F.; Diamantini, G.; Pala, Daniele; Riccioni, T.; Stasi, M. A.; Cabri, W.; Borsini, F.; Mor, Marco; Tarzia, G.; Minetti, P.. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 56:3(2013), pp. 1247-1261. [10.1021/jm301686s]
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors.
RIVARA, Silvia;PALA, Daniele;MOR, Marco;
2013-01-01
Abstract
A systematic modification of the caffeinyl core and substituents of the reference compound (E)-8-(3-chlorostyryl)caffeine led to the 9-deazaxanthine derivative (E)-6-(4-chlorostyryl)-1,3,5,-trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f) which acts as a dual antagonist of human A2a/MAO-B inhibitor (Ki(A2A) = 260 nM; IC50(MAO-B) = 200 nM; IC50(MAO-A) = 10 M) and dose dependently counteracts haloperidol-induced catalepsy in mice from 30 mg/kg by the oral route. The compound is the best balanced A2A antagonist /MAO-B inhibitor reported to date and it could be considered as a new lead in the field of anti-Parkinson’s agents. A number of analogs of 17f were synthesized and qualitative SARs are discussed. Two analogs of 17f, namely 18b and 19a, inhibit MAO-B with IC50 of 68 nM and 48 nM, respectively, being from five to seven folds more potent than the prototypical MAO-B inhibitor deprenyl (IC50 = 334 nM).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
